Generate Biomedicines, Inc. 8-K

What Happened
Generate Biomedicines, Inc. announced and furnished a press release on May 7, 2026 reporting its financial results for the quarter ended March 31, 2026. The company filed a Current Report on Form 8‑K (Item 2.02) to disclose these quarterly results; the press release is attached as Exhibit 99.1. The Company states the information is being furnished (not “filed”) under the Exchange Act and therefore is not subject to Section 18 liability.

Key Details

• The press release was issued May 7, 2026 and covers the quarter ended March 31, 2026.
• The press release is furnished as Exhibit 99.1 to the Form 8‑K.
• The 8‑K reports under Item 2.02 (Results of Operations and Financial Condition) and includes Exhibit 99.1 (press release).
• The Form 8‑K was signed by Jason Silvers, President and Chief Financial Officer, dated May 7, 2026.

Why It Matters
This filing signals that Generate Biomedicines has publicly reported its latest quarterly earnings and operational results; investors should review the attached press release for specific figures on revenue, earnings/losses, cash position, and any commentary on business progress or outlook. Note the company labeled the press release as furnished (not filed), which is a legal distinction about liability under Section 18 of the Exchange Act but does not change the substance of the disclosed quarterly results.